Pulnovo Medical Begins First Enrollment in Portugal for PADN Study on Pulmonary Hypertension with Left Heart Disease

SHANGHAI, July 2, 2024 – Pulnovo Medical Limited, a globally recognized pioneer in medical devices for Pulmonary Hypertension (PH) and Heart Failure (HF), has announced the successful initiation and enrollment of the first two patients in its global multicenter clinical study. This study aims to investigate the effectiveness of percutaneous pulmonary artery denervation (PADN) in treating pulmonary hypertension associated with left heart disease. The landmark event occurred at Centro Hospitalar Universitário de Lisboa Central - Hospital de Santa Marta in Portugal, marking Pulnovo Medical's significant step towards global deployment of its innovative technology.

The procedures were conducted under the guidance of Professor Hang Zhang from Nanjing Medical University Affiliated Nanjing Hospital, with the operations performed by Prof. Ruben Ramos and his medical team. The PADN procedures were carried out smoothly, with the devices proving to be user-friendly, and the results were outstanding. The Portuguese medical team was impressed by the PADN technology's safety and efficacy, backed by extensive data over the years. Clinical parameters indicated promising outcomes, attributing the success to the products' comprehensive design and high-precision algorithm control, which ensured stable energy output and effective surgical results.

Prof. Ruben Ramos commented on the PADN technology, stating, "PADN technology demonstrates significant potential in treating pulmonary hypertension associated with left heart disease. We are thrilled to be the first in Europe to participate in this global clinical study. Our team is optimistic about this project and looks forward to offering more treatment options to European pulmonary hypertension patients through this study. PADN is not just a new treatment method but also brings renewed hope to patients suffering from pulmonary hypertension."

Jessie Lian, CEO of Pulnovo Medical, emphasized the importance of the PADN global multicenter clinical study, saying, "This study is one of our key projects dedicated to innovative treatment technologies in the cardiovascular field. As an emerging treatment, PADN holds immense potential and prospects. The post-operative results of PADN's first overseas application reflect the current academic borderlessness. Moving forward, we will continue to advance our global business and promote the teaching and adoption of PADN technology."

Cynthia Chen, Chairlady of Pulnovo Medical, also expressed her pride in the successful first enrollment in the European multicenter clinical study of PADN in Portugal. She remarked, "This achievement marks the acceleration of our technology's global progress. We will continue to advocate for the global application of PADN, ensuring that more patients can benefit from this innovative therapy."

Pulnovo Medical's successful initiation of the global PADN clinical study and the first patient enrollments in Portugal highlight the company's commitment to advancing treatment options for pulmonary hypertension. The PADN technology, with its proven safety and efficacy, promises to bring significant improvements to the treatment of pulmonary hypertension associated with left heart disease, providing new hope to patients worldwide. As the study progresses, the potential benefits of PADN technology are expected to reach a broader patient population, reinforcing Pulnovo Medical's position as a leader in innovative cardiovascular treatments.